In addition to this study, Herbel and colleagues reported the results of an ongoing study investigating the expression of THY1 and EpCAM on the surface of ovarian cancer cells and the suitability of these target antigens for ovarian cancer CAR-T therapy with the aim of addressing the “on-target off-tumor” toxicity associated with this platform of cancer immunotherapy (84). The gene discussed is THY1; the disease is ovarian cancer.